Abstract: Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a CB1 antagonist/ inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level.

Abstract: Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a CB1 antagonist/ inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level.

Abstract: Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a CB1 antagonist/inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level.

Abstract: Functional near infrared spectroscopy (fNIRS) imaging is utilized to measure the influence of stimulation in real time. An fNIRS imaging device is integrated into a transcranial direct current stimulation (tDCS) stimulator by embedding fNIRS optodes on the tDCS stimulating electrodes. During tDCS stimulation, blood oxygenation levels are measured. For example, concentrations of oxyhemoglobin and deoxyhemoglobin are measured and compared to the concentrations of a baseline resting state to provide feedback on the efficacy of tDCS. Based on the feedback, a tDCS threshold and a dose-response relation for a particular subject can be quantified, and individualized stimulation parameters can be determined for the particular subject.

Abstract: Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of a CB1 antagonist/inverse agonist receptors, and to the use of a pharmaceutical composition which comprises a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level.

Abstract: An apparatus and a related method for the deep brain stimulation have been invented wherein the parameters of the stimulation supplied at the human nervous system level are adjusted and optimized continuously by the analysis of the bioelectric signals coming from the tissue adjacent the stimulation electrode itself, adapting the therapy continuously and in line to the patient's clinical state. The apparatus is constituted at least by an electro-catheter (1) implantable in a patient's brain and equipped with four contacts (4, 5, 6, 7). Then, there is at least a stimulation module (9) which generates the stimulating signal (15) sent to the electro-catheter (1) and in particular to one of the contacts thereof (6). The electro-catheter (1) contemporarily sends a signal characterizing the brain activity coming from the tissue involved by the stimulating signal (15) to an acquisition module (8).

Abstract: A method for evaluating an effect of a psychotropic compound or a treatment on a neuronal activity of an animal including determining a change in the amount of information generated by neurons in response to at least one repeatedly applied stimulus, wherein the change is caused by administering the psychotropic compound or a treatment. Also provided is a method of screening psychotropic compounds for effectiveness on an animal which involves using a change in sensory discrimination in a population of neurons of the animal, wherein the sensory discrimination is obtained in response to one or more stimuli repeatedly applied to the animal and wherein a change in the sensory discrimination occurs due to administering said psychotropic compounds to the animal.

Abstract: An apparatus and a related method for the deep brain stimulation have been invented wherein the parameters of the stimulation supplied at the human nervous system level are adjusted and optimized continuously by the analysis of the bioelectric signals coming from the tissue adjacent the stimulation electrode itself, adapting the therapy continuously and in line to the patient's clinical state. The apparatus is constituted at least by an electro-catheter (1) implantable in a patient's brain and equipped with four contacts (4, 5, 6, 7). Then, there is at least a stimulation module (9) which generates the stimulating signal (15) sent to the electro-catheter (1) and in particular to one of the contacts thereof (6). The electro-catheter (1) contemporarily sends a signal characterizing the brain activity coming from the tissue involved by the stimulating signal (15) to an acquisition module (8).